OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-05-31-accounts

Trustees’ Annual Report for the period:

From 1 June 2024 to 31 May 2025 Charity name: British Neuro-Oncology Society Charity registration number: 1203502

Objectives and Activities

SORP reference
Summary of the purposes
of the charity as set out in
its governing document
Para 1.17 The objects of The British Neuro-
Oncology Society are:
The relief of sickness and the preservation
of health for patients suffering with
tumours of the brain and central nervous
system by improving treatment through:
(1) Educating the public in general
(particularly medical practitioners,
nurses, allied health professionals, and
the wider scientific community in the
United Kingdom) on the subject of
neuro-oncology.
(2) Promoting research for the public
benefit in all aspects of neuro-
oncology.
(3) Raising awareness of neuro-oncology
and of treatments and techniques in
clinical practice among the general
public, health professionals and policy
makers.
(4) General advocacy for the interests of
brain cancer patients, their families and
carers.
Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.
Para 1.17 and
1.19
• Delivery of the BNOS annual scientific
meeting, held in Cambridge from 17-
19 July 2024
• Awarding 25 bursaries worth up £400
each to nurses, allied health
professionals, trainees and researchers
to subsidise the costs of attending the
conference
• Awarding the first BNOS Global Neuro-
Oncology bursaries worth up to £2000
each, to health care professionals
workingin low/middle income

1

countries to enable them to attend the
Cambridge meeting
• Formation of the Clinical Committee to
support BNOS’s role as a stakeholder
and help inform the clinical, academic
and patient community about
developments in the diagnosis,
treatment and management
approaches for brain tumour patients.
• Delivery of an online Allied Health
Professional Educational Day
• Delivery of a neuro-oncology grant
workshop for early career researchers
• Delivery of webinars relating to neuro-
oncology
• The BNOS website hosts useful
information about treatment pathways
for patients and their careers and has
free resources for professionals. It also
acts a signpost to news, events,
research and job opportunities across
the neuro-oncology community. In
addition, there is a private members-
only website area with additional
resources, such as recordings from
previous conferences and webinars
• Attendance of BNOS representatives at
other charity and professional body
meetings (SBNS, Joint Neuroscience
Council (JNC), Royal College of
Surgeons (RCS) Cancer Services
Committee
Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit
Para 1.18 Trustees have acted in line with the
Society’s constitution and have complied
with their duty under the Charities Act
2011 to have due regard to the guidance
on public benefit published by the Charity
Commission.

Additional information

Additional information
SORP reference
Contribution made by
volunteers
Para 1.38 The day-to-day running and decision-
making of BNOS is carried out by the
BNOS Council and Executives. The
Council represents the broad spectrum of
disciplines within the field of neuro-
oncology. The Council is overseen by the
Executives (President, Vice President,
Honorary Treasurer, Honorary Secretary
and Meetings Secretary). In addition, to
the Council, there are four Committees
(Academic, Patient Centred Care, Student
and Trainee,and Clinical)who have

2

additional volunteer members. The Committees plan and deliver online events such as educational webinars and help to support BNOS’s role as a stakeholder, informing the clinical, academic and patient communities about relevant drug and technology developments. They also foster multidisciplinary collaboration and represent students and trainees. Further volunteer contribution is made by the Local Organising Committee for the annual conference. Each annual conference host unit will convene a committee to decide the conference theme, devise the scientific programme, invite speakers, organise the social events and review abstracts amongst other activities associated with the successful delivery of the conference.

Achievements and Performance

SORP reference
Summary of the main
achievements of the charity,
identifying the difference
the charity’s work has made
to the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.
Para 1.20 The 2024 Annual Conference was held in
Cambridge. This is an educational and
networking event which attracts a diverse
and multidisciplinary audience. The
theme was ‘Working together for
precision care’. There were 314 individual
attendees across the 3-day meeting. 95
abstracts were submitted and accepted.
Where consent was given by the authors,
the abstracts were published as a
supplement in the journal Neuro-
Oncology. 25 individuals who may
otherwise have not been able to attend
were supported with a £400 bursary
towards the cost of registration,
accommodation and travel.
In recognition that the care and treatment
of brain tumour patients is a challenge,
not only in the UK, but also in the rest of
the world, we invited health care
professionals working in low/middle
income countries to apply for bursaries to
attend the 2024 BNOS conference. We
received 21 applications and awarded
four bursaries worth £2000 to cover visas,

3

travel, accommodation, registration and food. We also facilitated connections between successful applicants and host institutions so that recipients were able to spend time after the conference with clinical teams in the UK. The bursaries were given to a neurosurgeon from Malawi, an oncologist from Nigeria, a psychiatrist from Indonesia and a neurosurgeon from Cameroon. Unfortunately, the delegate from Cameroon had his visa refused and was unable to travel to the UK. Our delegates from Malawi and Nigeria spent two weeks on an observership at The Walton Centre and The Clatterbridge Cancer Centre, Liverpool while the Indonesian delegate made contacts in Birmingham. Their feedback on the opportunity and experience was overwhelmingly positive, and we hope to continue to offer these bursaries. A Clinical Committee was established in recognition of the rapidly developing clinical environment in neuro-oncology. The Committee’s role is to focus on emerging clinical issues including new diagnosis, treatment and management approaches for brain tumour patients. Committee members support BNOS’s role as a stakeholder in various settings and help inform the clinical, academic and patient community about developments by: • Horizon scanning to help make sure BNOS is aware of new treatments/biomarkers etc. in different settings • Helping/contributing when we are asked to be stakeholder in e.g. NICE and technology assessments • Ensuring BNOS has a voice in any new national/international clinical and/or funding initiatives (e.g. GTABs, research MDT, NIHR programmes, new technology calls etc.) • Being an interface with the BNOS Patient Centred Care Committee • Helping to shape clinical aspects of other BNOS activities, including education and congress

4

The Committee has produced position statements on Tumour Treating Fields for GBM, and Vorasidenib in Low Grade Glioma; is engaging with NICE about access to other agents including BRAF inhibitors and is working closely with the other brain tumour charities. A free online event for allied health professionals was held on 4 March. The theme was ‘Update in brain tumours’ and topics covered were end of life care and best practice, awake craniotomy, novel oncology therapies explained, genomics. The day was extremely well received, and we hope to make this an annual event. A grant workshop for early career researchers was held at Nottingham University on 25 April. Insight into grant writing was provided by presentations from funders and researchers within the neuro-oncology field, followed by the opportunity to apply for 2x pump-prime awards of £5500, funded by The Brain Tumour Charity, Novocure and Brain Research UK. Grants were awarded to the following projects which should be completed by 1[st] April 2026: • Evaluating metabolic and cytotoxic effects of electroactive drug delivery in a 3D glioblastoma coculture modelExploring the role of hypoxiadriven extracellular vesicles in mediating neuron-tumour communication in paediatric brain tumours We delivered a variety of webinars from guest speakers aimed at different audiences, covering paediatric neurooncology and translational research.

Financial Review

Review of the charity’s
financial position at the end
of the period
Para 1.21 The charity held £107,661 in unrestricted
cash funds at 31 May 2025 (2024:
£130,185). The charity received £20,387
unrestricted in theyear and £6,000 of

5

restricted income which was fully
expended. In the prior period all income
and expenditure was unrestricted.
Statement explaining the
policy for holding reserves
stating why they are held
Para 1.22 The charity holds reserves in order to fulfil
its charitable objects. The charity aims to
hold more than 12 months of operational
spend in unrestricted cash reserves,
equivalent to approximately £45,000 at
24/25 levels. At 31 May 2025, the charity
held £108k of reserves. Trustees are
reviewing the current level of reserves
and how best to utilise the excess above
the policy in furtherance of the charity's
objects.
Amount of reserves held Para 1.22 The charity held £107,661 in unrestricted
cash funds at 31 May 2025, (2024:
£130,185)and no restricted funds.
Reasons for holding zero
reserves
Para 1.22
Details of fund materially in
deficit
Para 1.24
Explanation of any
uncertainties about the
charity continuing as a
goingconcern
Para 1.23 The trustees consider that there are no
uncertainties about the charity as a going
concern.

Additional information

The charity’s principal
sources of funds (including
anyfundraising)
Para 1.47 Income is raised through membership
fees and additional revenue is generated
through the annual conference.

Structure, Governance and Management

Description of charity’s trusts: Description of charity’s trusts:
Type of governing
document
Para 1.25 Constitution date 3 July 2024
How is the charity
constituted?
Para 1.25 Charitable Incorporated Organisation
Trustee selection methods
including details of any
constitutional provisions
e.g. election to post or
name of any person or
body entitled to appoint
one or more trustees
Para 1.25 The trustees were appointed at the date
of the charity incorporation and by
majority agreement by the Board of
Trustees.

6

Reference and Administrative details

Charityname British Neuro-OncologySociety
Other name the charityuses BNOS
Registered charitynumber 1203502
Charity’s principal address The Gateway
85-101 Sankey St
Warrington
Cheshire
WA1 1SR

Names of the charity trustees who manage the charity

Trustee name Office (if any) Dates acted if not
for whole year
Name of person (or
body) entitled to
appoint trustee (if
any)
Paul Grundy Chair
Andrew Brodbelt To 19 June 2025
Colin Watts
Harpreet Hyare
Susan Short To 19 June 2025
Victoria Skinner Since 11 April 2025
Catherine Fraher Since 8 August
2025

Declarations

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

Signature(s)
Full name(s) Paul Grundy
Position Chair of Trustees
Date 24 March 2026

7

Independent examiner's report

To the trustees of

British Neuro-Oncology Society

I report to the trustees on my examination of the accounts of British Neuro-Oncology Society (the charity) for the year ended 31 May 2025, which are set out on pages 9 - 10.

Respective responsibilities of trustees and examiner

As the trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (‘the Act’).

I report in respect of my examination of the charity’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Dougal Howard

Date: 24 March 2026 Dougal Howard ACA Member of the ICAEW

Godfrey Wilson Limited

Chartered accountants and statutory auditors 5th Floor Mariner House

62 Prince Street Bristol BS1 4QD

8

British Neuro-Oncology Society

Receipts and payments account

For the period ended 31 May 2025

Receipts
Donations
Conference
Grants
Interest
Other income
Subscriptions
Total receipts
Payments
Admin
Annual membership
Bank charges
Bursaries
Conference
Events
Freelancers
Governance
Website
Accountancy
Travel expenses
Total payments
Net receipts / (payments)
Cash funds at 31 May 2024
Cash funds at 31 May 2025
Restricted
£
-
-
6,000
-
-
-
6,000
-
-
-
6,000
-
-
-
-
-
-
-
6,000
-
-
-
2025
Total
£
£
-
-
-
-
-
6,000
1,452
1,452
185
185
18,750
18,750
20,387
26,387
245
245
383
383
22
22
9,765
15,765
13,522
13,522
461
461
15,301
15,301
-
-
1,224
1,224
1,680
1,680
308
308
42,911
48,911
(22,524)
(22,524)
130,185
130,185
107,661
107,661
Unrestricted
2024
Total
£
99,893
59,811
-
1,561
25
15,564
176,854
2,434
374
27
6,657
24,374
48
11,351
216
1,188
-
-
46,669
130,185
-
130,185

All receipts and payments were unrestricted in the prior reporting period.

Restricted funding of £6,000 was received to fund workshops. It was fully spent in the year.

Trustee expenses in the current period were nil (2024: £95 for travel expenses reimbursed to one trustee).

9

British Neuro-Oncology Society

Statement of assets and liabilities

Statement of assets and liabilities
As at 31 May 2025
Cash funds
Cash at bank and in hand
Total cash funds
Cash funds
Restricted funds
Unrestricted funds
General funds
Total cash funds
2025
107,661
107,661
-
107,661
107,661
2024
£
130,185
130,185
-
130,185
130,185

Approved by the trustees on date 24 March 2026 and signed on their behalf by

Paul Grundy - Chair

10